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1097-97 Treatment of Pulmonary Arterial Hypertension 
Aseoclated With Congenital Heart Disease With 
Intravenous Epoprostanoh Impact of Therapy on Timing 
of Transplantation 
David W. Butzel. Vallerie V. McLaughlin, Stuart Rich, Rush-Prasbyterian-St. Luke's 
Medical Center, Chicago, Illinois. 
Introduction: Intravenous epoprostenol (EPO) improves exercise tolerance, hemodynam- 
ics, and survival in primary pulmonary hypertension (PPH), Patients with pulmonary 
hypertension (PH) associated with congenital heart disease (CHD) demonstrate 
improved hemodynamics with EPO over the short term, The objective of this study was 
to determine the long-term effects of EPO in CHD and implications for timing of lung or 
heart-lung transplantation. 
Methods: The Rush database of 264 patients with PH treated with EPO since 1991 was 
queried for patients with CHD. The sixteen patients with CHD were matched in a 2:1 
fashion with 32 PPH patients for age, gender, and functional class (FC) at the time of 
EPO initiation. Hemodynamics and exercise time at time of EPO initiation and at one 
year was compared using students paired t-test. Survival over 5 years was analyzed 
using Kaplan-Meier analysis. 
Results: EPO resulted in similar improvements in hemodynamics and treadmill times in 
both PPH and CHD at 1 year. In CHD the PVR declined by 30% from 17 to 12 Wood 
units (p<0.001), the systemic arterial 02 saturation improved from 88 to 91% (p=0,024), 
and the treadmill time improved 118% from 226 to 492 seconds (p=0.023). The 1,3, and 
5 year survivals were 93%, 83%, and 81% for CHD versus 84%, 66%, and 62% for PPH 
respectively. 
Conclusion: The favorable response of CHD to EPO is similar to that of PPH. The sur- 
vival of CHD with EPO exceed that of PPH and that of lung or heart-lung transplantation 
which has a 1, 3, and 5 year survival of 60%, 48%, and 40%. The treatment of patients 
with PH associated with CHD with EPO may delay or avoid need for transplantation. 
1097-98 Sildenafil (Viagra) in Childhood and Neonatal 
Pulmonary Hypertension 
Simon Erickson, Janetta Reyes, Des Bohn, tan Adatia, Hospita/for Sick Children, 
Toronto, Ontario, Canada. 
Bacground: Cyclic guanosine monosphate (cGMP) mediates vasodilation induced by 
nitdc oxide (NO). Inhibition of type 5 phosphodiesterase ( present in high concentration in 
pulmonary vasculature) elevates cGMP and promotes vasodilation, Therefore, we inves- 
tigated the effect of oral sildenafil in pulmonary hypertension. Methods: We administered 
oral sildenafil (0.25 -0,5 mg/kg) to 16 patients ( median age 6 years, range 3 days to 18 
years, gender 7M,9F). All patients had pulmonary hypertension defined by echocardio- 
graphy or catheter measurement. Dudng cardiac cathetedsation (n=6) we measured 
hemodynamics before and 20 minutes after administration of sildenafil, We administered 
sildenafil to 5 patients with refractory suprasystemic pulmonary hypertension after grad- 
ual withdrawal of inhaled NO, despite alkanilisation, ( diagnoses included repair of con- 
genital diaphragmatic hernia n=3, and pulmonary vein stenosis n=2). Five patients 
received chronic sildenafil therapy, given 4 times a day ( primary pulmonary hypertension 
n=3, secondary pulmonary hypertension =2). Subsequent evaluation was by echocar- 
diography and distance walked in 6 minutes . Results:During cardiac cathetedsation 
mean pulmonary artery pressure decreased from 50±8 to 38±12 mmHg (p<0.05) and 
indexed pulmonary vascular resistance decreased from10.5±4.9 to 7.6±4.6 Wood Units 
m2 (p<0.05). There were no changes in mean systemic pressure 64±4 to 65±8 mmHg, 
systemic vascular resistance 17.1±4.6 to 17.6±5.2 Wood Units m2 or cardiac index 
4.0±1.2 to 4.0 ±1.2 I/min/m2. In 5 patients sildenafil attenuated the rise in pulmonary 
artery pressure and permitted iscontinuation of NO without hemodynamic instability 4-6 
hours after oral sildenafiL In the chronic therapy group 3/5 patients followed for a median 
of 12 weeks had improvements in 6 minute walk distance of 200%. Conclusion: Our 
results suggest that oral sildenafil selectively decreases pulmonary vascular resistance, 
attenuates rebound pulmonary hypertension and facilitates weaning of prolonged inhaled 
NO therapy and improves distance walked in 6 minutes. Sildenafil offers promise in the 
treatement of acute and chronic pulmonary hypertension. 
1097-99 Basal Pulmonary Vascular Resistance and Its Response 
to Exogenous Nitric Oxide Late After Fontan Operation 
Sachin Khambadkone, Jia Li, Grahman Derrick, Shay Cullen, John Deanfield, Marc de 
Leval, Andrew Rodington, Great Ormond Street Hospital, London, United Kingdom. 
Background: The pulsetile nature of pulmonary blood flow is important for shear-stress 
mediated release of endothelium-derived nitric oxide (NO) and lowering pulmonary vas- 
cular resistance (PVR) by passive recruitment of capillaries. Normal pulsatile flow is lost 
or markedly attenuated after Fontan-type operations, but to date, there are no data on 
basal pulmonary vascular resistance and its responsiveness to exogenous nitric oxide, at 
late follow up in these patients. 
Methods: We measured indexed pulmonary vascular resistance (PVRI), using Fick prin- 
ciple to calculate pulmonary blood flow, with respiratory mass spectrometry to measure 
oxygen consumption, in 10 patients (median age 11.2yr, range 8- 17 yrs, 7 male, 3 
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female) at mean 5 yrs after a Fontan-type operation (4 atriopulmonary connections, 2 lat- 
eral tunnels, 3 extrecardiac onduits, 1 intrsatrial tube). Ventilation under general anaes- 
thesia during cardiac catheterisetion was adjusted to avoid alveolar hypoxemia or 
hypoventilation. Measurements were made before and after NO inhalation at 20 ppm for 
10 minutes. 
Results: The baseline cardiac index was 2.5 + 0.64 L/rain/m2. The basal PVRI was 2.07 
+ 0.89 Wood units/m2 (mean + SD) end showed a significant reduction to 1.48 + 0.37 
(p=0.03) after NO inhalation. 6 patients showed pulsetility on the pulmonary artedal pres- 
sure trace (4 atriopulmonary connections, 2 lateral tunnels), however, they did not differ 
significantly from those with a non-pulsatile weveform, either in terms of basal PVR (2.11 
.+_ 1.19 and 2.02 + 0.05, p=0.8) or response to NO (1.37 + 0.33 end 1.63 + 0.40, p = 0.11), 
respectively. 
Conclusion: PVR fails with exogenous nitric oxide late after Fontan-type operation. 
These data suggest that endogenous NO production may be reduced late after Fontan- 
type operation, even in patients with some pulsetility in the pulmonary circulation. Thera- 
peutic strategies to enhance pulmonary endothelial NO release may have a role in these 
patients. 
1097-100 Presenting Features and Clinical Outcomes for  Children 
With Metabolic Cerdiomyopethise 
Piers E. Daubanev. Alan Nogent, Patty Chondros, Stephen Kahler, John Cadin, Robert 
G. Weintraub, National Australian Childhood Cardiomyopathy Study, Royal Children's 
Hospital, Melbourne, Australia. 
Background: Metabolic diseases are an important cause of childhood cardiomyopathy. 
This review examines the presenting features and clinical outcomes for children with 
these conditions enrolled in the National Australian Childhood Cardiomyopathy Study 
(NACCS). 
Methods: NACCS is e population-based study including all children in Australia with CM 
presenting <10 years of age from 1987-97. Cases were collected from all paediatric ar- 
diologists and paediatdc cardiac sentres, as well as from adult cardiologists, regional 
paediatricians, cardiac transplant centres and coronial records. Cases were classified 
according to accepted WHO guidelines. Metabolic diseases were defined as those with a 
biochemical abnormality aetiologically linked to the cardiomyopathy. Children with pro- 
gressive neuromuscular diseases and those with dominant systemic or neurological 
symptoms were excluded. 
Results: There were 28 children with metabolic conditions (8.9% of study population) 
including 6.5% of patients with DCM, 2.5% with HCM and 32.6% of patients with unclas- 
sified cardiomyopathy. Congestive heart failure at presentation occurred in 21/28 (75%). 
Commonest diagnoses were respiratory chain enzyme deficiencies (10), Barth syndrome 
(8), camitine deficiency syndromes (4) and fatty acid oxidation defects (4). Children with 
respiratory chain enzyme deficiencies had variable cardiomyopathiss including DCM, 
HCM and mixed hypertrophy with systolic dysfunction. 7/8 (87.5%) children with Barth 
syndrome had LV non-compaction (LVNC) and the other had DCM. Berth syndrome was 
present in 7/29 (24%) patients with LVNC. 6 of 8 with unclassified cardiomyopathy 
(increased LV wall thickness with systolic dysfunction) had metabolic disease. Overall 
mortality was 17/28 (60.7%). In 6/10 the diagnosis of a respiratory chain defect was not 
made until after death. 
Conclusions: There is considerable clinical heterogeneity among children with metabolic 
cardiomyopathies. They should be suspected in children with atypical cardiac features. 
Barth syndrome should be excluded in males with LVNC. Routine assay of respiratory 
chain enzymes on postmortem or explanted hearts may improve the diagnostic yield. 
I097-I01 Risk Factors Associated With Posttrsnsplant Coronary 
Artery Dlsease in Pediatric Cardlac Transplant 
Recipients 
Nahidh Haseniya, Leonard Bailey, Steven Gundry, Anees Razzouk, Richard Chinnock, 
Paul A. Checchia, Lomb Linda University Children's Hospital, Loma Linda, California. 
Background: Post-transplant coronary artery disease (PTCAD) is associated with a high 
mortality and a significant dsk of graft failure. A number of associated factors have been 
postulated including ischemic time, gender mismatch, cytomegalovirus (CMV) infection, 
and rejection history. However, to date, the cause of PTCAD is not currently known. 
Purpose: The purpose of the current study is to examine possible factors associated with 
PTCAD in a pediatric transplant population. 
Methods: All pediatric patients less than 18 years of age who had undergone cardiac 
transplantation at Loma Linda University Children's Hospital during the years 1985-2001 
were retrospectively reviewed. 
Results: A total of 338 infants and children underwent orthotopic ardiac transplantation. 
Overall survival is 70%. Forty-three patients (12.1%) developed PTCAD. The average 
time to PTCAD was 5.96 yrs (range 1.14 - 14.45). Mortality within the PTCAD group was 
significantly higher that the remaining transplant population (57% vs. 26%, p<0.001). 
Patients who developed PTCAD had a higher number of rejection episodes per year 
(1.06 vs 0.49, p--0.001) There was a lower incidence of CMV found in the donors of those 
patients who went on to develop PTCAD (40% vs 60%, p=0.008). Patients who devel- 
oped PTCAD had a shorter overall dopemine requirement in the post-operative peded 
(3.87 vs 5.10 days, p<0.05). Factors not associated with PTCAD included: ischemic time 
of the graft, gender, gender mismatch, blood type, donor to recipient weight ratio, right 
and left ventricular end-diastolic pressure, days on mechanical ventilation in the post- 
operative pedod, CMV status of the recipients, or HLA tissue typing mismatch. 
Conclusion: PTCAD among pediatric cardiac transplant recipients ignificantly increases 
mortality. PTCAD is associated with the number of rejection episodes. The role of CMV 
infection remains unclear. PTCAD is not associated with isohemic times, as has been 
previously suggested. Eady and frequent coronary artery evaluation in children with fre- 
quent rejection episodes may be warranted. 
